עדכוני AACR 2019

CT195 / 9 - Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response

Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results: from the KEYNOTE-028 and KEYNOTE-158 studies
Mar 29 - April 3, 2019 - AACR 2019, American Association for Cancer Research Annual Meeting - Atlanta, Georgia, USA. Abstract CT073

Outcomes among patients (pts) with metastatic nonsquamous NSCLC with liver metastases or brain metastases treated with pembrolizumab (pembro) plus pemetrexed-platinum: Results: from the KEYNOTE-189 study
Mar 29 - April 3, 2019 - AACR 2019, American Association for Cancer Research Annual Meeting - Atlanta, Georgia, USA. Abstract CT043

CT036 - A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy

CT032 - TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

CT033 - TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)

CT034 - Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study

CT039 - A Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) S1609: The neuroendocrine cohort

4460 - Clinical utility of comprehensive cell-free DNA (cfDNA) analysis to identify genomic biomarkers in newly diagnosed metastatic non-small cell lung cancer (mNSCLC)